TPBCs harbored a median of 31.5 nonsynonymous somatic mutations per tumor, while ER+PR-HER2+, ER-PR+HER2+ and ER-PR-HER2+ breast cancers harbored 50.5, 40 and 40.5 nonsynonymous somatic mutations per tumor, respectively. This evidence concerns the gene ERBB2 and neoplasm.